Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Procaps Group SA (PROC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PROC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.26% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 113.95M USD | Price to earnings Ratio 1.53 | 1Y Target Price 5 |
Price to earnings Ratio 1.53 | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 0.17 | 52 Weeks Range 0.50 - 3.77 | Updated Date 06/29/2025 |
52 Weeks Range 0.50 - 3.77 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.66 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.61% | Operating Margin (TTM) 11.13% |
Management Effectiveness
Return on Assets (TTM) 6.28% | Return on Equity (TTM) 37.37% |
Valuation
Trailing PE 1.53 | Forward PE 81.3 | Enterprise Value 3489500436 | Price to Sales(TTM) 0.28 |
Enterprise Value 3489500436 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 8.43 | Enterprise Value to EBITDA 28.27 | Shares Outstanding 112824000 | Shares Floating 17150379 |
Shares Outstanding 112824000 | Shares Floating 17150379 | ||
Percent Insiders 83.03 | Percent Institutions 2.93 |
Analyst Ratings
Rating 1 | Target Price 5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Procaps Group SA
Company Overview
History and Background
Procaps Group SA is a pharmaceutical and nutraceutical company specializing in soft gelatin capsules. Founded in 1977 in Colombia, it has expanded its global presence through strategic acquisitions and product innovation.
Core Business Areas
- Softgel Manufacturing: Procaps is one of the largest softgel manufacturers globally, producing a wide array of encapsulated products for pharmaceutical, nutraceutical, and consumer health applications.
- Rx Formulations: Development and manufacturing of prescription drugs, primarily in Latin America.
- OTC Brands: Development, manufacturing, and marketing of over-the-counter consumer health brands.
Leadership and Structure
The leadership team consists of Ruben Minski (CEO), and the company operates with a functional organizational structure across its business units and geographies.
Top Products and Market Share
Key Offerings
- Market Share (%): 5
- Softgel Capsules: Procaps' core offering, including a wide range of formulations and dosages. The company is estimated to have around 5% global market share in softgel contract manufacturing. Competitors include Catalent, Lonza and Thermo Fisher.
- Rx Pharmaceuticals: Prescription medications focused on specific therapeutic areas like cardiovascular health and women's health. Revenue varies by country and product, competitor depends on the pharmaceutical product
- Market Share (%): 2
- OTC Products: Over-the-counter medications sold directly to consumers, including vitamins, supplements, and pain relievers. Revenue varies by product and market.
Market Dynamics
Industry Overview
The pharmaceutical and nutraceutical industries are experiencing growth due to increasing healthcare spending, aging populations, and rising consumer awareness of preventive health. Market dominated by large players but with significant demand for specialized manufacturing like softgels.
Positioning
Procaps is positioned as a leading softgel manufacturer and a regional player in Rx and OTC markets, with a focus on innovation and quality. The company's competitive advantages include its manufacturing expertise, vertical integration, and established presence in Latin America.
Total Addressable Market (TAM)
The global pharmaceutical and nutraceutical market is estimated at over $1 trillion. Procaps is positioned to capture a larger share of the softgel and specialized manufacturing segment.
Upturn SWOT Analysis
Strengths
- Leading softgel manufacturing expertise
- Strong presence in Latin America
- Vertical integration
- Diverse product portfolio
- Innovative capabilities
Weaknesses
- Dependence on softgel market
- Geographic concentration in Latin America
- Exposure to currency fluctuations
- High debt load
Opportunities
- Expanding softgel applications
- Growing demand for nutraceuticals
- Strategic acquisitions
- Entering new markets
- Partnerships with pharmaceutical companies
Threats
- Increased competition
- Regulatory changes
- Economic instability in Latin America
- Supply chain disruptions
- Price pressures
Competitors and Market Share
Key Competitors
- Catalent (CTLT)
- Lonza Group (LZAGY)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Procaps has a strong presence in Latin America and specialized expertise in softgels, but it faces competition from larger, more diversified players with greater resources and broader geographic reach.
Major Acquisitions
Grupo Somar
- Year: 2021
- Acquisition Price (USD millions): 140
- Strategic Rationale: Expanded OTC product portfolio and presence in Brazil.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increasing softgel demand and expansion into new markets.
Future Projections: Future growth is projected to be driven by increased demand for softgels, strategic acquisitions, and expansion into new markets.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, developing new softgel formulations, and pursuing strategic partnerships.
Summary
Procaps is a leading softgel manufacturer with a strong presence in Latin America. Its specialized expertise and vertical integration are key strengths. However, it faces competition from larger players and exposure to economic instability. Strategic acquisitions and expansion into new markets are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Procaps Group SA Investor Relations
- Industry Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market data and competitor information are based on estimates and may vary. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Procaps Group SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-09-30 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 5500 | Website https://www.procapsgroup.com |
Full time employees 5500 | Website https://www.procapsgroup.com | ||
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.